- 6 Downloads
Positive data for Epigenomics’ pharmacodiagnostic test
At the 2005 meeting of the American Society of Clinical Oncology (ASCO), Epigenomics released data confirming that its proprietary DNA methylation markers are closely correlated with disease recurrence and prediction of therapy response in early breast cancer.
Currently, combined chemotherapy and endocrine therapy is recommended as the treatment of choice for most breast cancer patients to prevent the disease from returning after surgical resection. However, a large proportion of patients treated with endocrine therapy alone have an excellent prognosis after 10 years and therefore do not need additional chemotherapy with agents such as tamoxifen. Epigenomics contends that DNA methylation of PITX2 could be used as a guide to avoid unnecessary — and potentially harmful —chemotherapy for many of these patients. At ASCO, Epigenomics presented results from a large, multicenter clinical study validating the DNA methylation marker...
- 1.Epigenomics. Epigenomics AG validates DNA methylation test as predictor of disease recurrence in breast cancer patients. Media release: 17 May 2005Google Scholar
- 2.European Pharmaceuticals. Epigenomics: Latest breast cancer marker data as expected. Lehman Brothers Equity Research (2005)Google Scholar
- 3.Nanogen. Study using Nanogen assay confirms NT-proBNP to have utility as predictor of mortality in patients with severe congestive heart failure. Media release: 8 Jun 2005Google Scholar
- 5.Loyola University Health System. Loyola researchers discover congestive heart failure biological marker which speeds diagnosis, treatment. Media release: 7 Jun 2005Google Scholar
- 6.National Institute of General Medical Sciences. Genetic variation alters response to common anti-clotting drug. Media Release: 2 Jun 2005Google Scholar
- 7.EurekAlert. Phase I study examines biomarkers for response to erlotinib in glioma. Media release: 14 Jun 2005Google Scholar